Deletion of Trpm4 increases post-infarction inflammation and fibrosis without improving long-term survival or cardiac function in mice, suggesting caution for future therapeutic attempts to inhibit TRPM4 post-MI.
Answers are grounded in this paper and cite their sources.
TRPM4 inhibition post-MI may heighten early inflammation and chronic fibrosis; leaves open its therapeutic viability pending targeted trials.
increases markers of cardiac and systemic inflammation within the first 24 h after MI, while inducing an earlier fibrotic transition at 72 h and more overall chronic fibrosis and angiogenesis at 5 wk. The descriptive, robust, and methodologically broad approach of this study sheds light on an important caveat that will need to be taken into account in all future therapeutic attempts to inhibit TRPM4 post-MI.
No takes yet. Share an insight, caveat, or question.
Boukenna et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: